BSX - Boston Scientific Corp Volatility & Greeks
This article provides a detailed overview of Boston Scientific Corp (BSX) including its stock performance, financial metrics, valuation ratios, and volatility indicators. It lists key data such as market capitalization, income, sales, price-to-earnings ratio, and various growth rates. The information is presented in a data-rich format, characteristic of financial screening platforms, without narrative commentary.
J&J's MedTech Segment Eyes Another Strong Quarter in Q2
Johnson & Johnson's (J&J) MedTech division is anticipated to report strong growth in Q2 2026, driven by recent acquisitions in cardiovascular health and new product launches, particularly in electrophysiology. Despite challenges from China's volume-based procurement program, the segment's performance, especially in Cardiovascular, Surgery, and Vision, is expected to reinforce investor confidence in its long-term growth potential. J&J's shares have outperformed the industry this year but are currently valued slightly higher than the industry average.
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility With Abbott's FreeStyle Libre 3 Plus CGM Sensor
Tandem Diabetes Care has made its t:slim X2 insulin pump, featuring Control-IQ+ technology, compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in several European countries, including the UK, Switzerland, Sweden, Finland, and Italy. This integration provides users with expanded CGM choices, allowing the FreeStyle Libre 3 Plus sensor to send glucose readings to the pump every minute for up to 15 days. The company plans to roll out this compatibility to additional countries later this year.
Insulet launches Omnipod 5 insulin system in Spain By Investing.com
Insulet Corporation has officially launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data management platform in Spain, making it the 20th country for Omnipod 5 and 26th market overall for Insulet's Omnipod products. This expansion targets Spain's 189,000 individuals with type 1 diabetes, enabling automated insulin delivery and data management for better diabetes care. Despite the aggressive international growth and 32% revenue increase, InvestingPro analysis suggests the stock is currently overvalued, while the company also faces recent product recall concerns and new analyst coverage.
Insulet launches Omnipod 5 and Omnipod Discover in Spain
Insulet Corporation has launched its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, marking its availability in the 26th country overall and 20th for Omnipod 5. The Omnipod 5 system is designed for type 1 diabetes patients aged two and older, automatically adjusting insulin delivery and being compatible with Abbott FreeStyle Libre 2 Plus and Dexcom G7 CGMs. Omnipod Discover is a web-based platform for data analytics aimed at improving therapy discussions.
Medtronic plc highlights its global medical technology role as investors monitor long-term growth
Medtronic plc, a major player in medical devices, is highlighted for its diversified portfolio and role in global medical technology. Investors focus on the company's long-term growth driven by recurring revenue from implanted therapies, innovation, and its engagement with digital health trends. The article discusses Medtronic's global footprint, revenue drivers, operational efficiency, and the structural tailwinds of an aging population, set against risk considerations like regulatory shifts and pricing pressures.
EW - Edwards Lifesciences Corp Volatility & Greeks
This article provides a detailed financial overview of Edwards Lifesciences Corp (EW), including its stock performance, market capitalization, income, sales, and various financial ratios. It also presents insider ownership and institutional ownership data, along with volatility measures and analyst recommendations. The data indicates strong recent performance and growth projections for the company.
Abbott Laboratories holds its footing as investors await the next catalyst
Abbott Laboratories remains a significant healthcare company with a diverse portfolio including diagnostics, medical devices, nutrition, and established pharmaceuticals. The company's business model is anchored by recurring demand in core healthcare categories, with products like FreeStyle Libre highlighting its device-led approach. Investors are looking to its medical device and diagnostics segment for future catalysts, as the stock maintains its identity on the NYSE.
Cardinal Health Kangaroo Joey Enteral Feeding Pump - A long-running workhorse in U.S. hospitals
The article highlights the Cardinal Health Kangaroo Joey Enteral Feeding Pump as a foundational product in U.S. hospitals and home care, valued for its reliability, compact design, and ease of use. It details the pump's features, clinical utility, and role in Cardinal Health's medical segment revenue, emphasizing its "longseller" status due to consistent performance and integration into healthcare workflows. The piece also touches on regulatory compliance, competitive landscape, and the pump's financial significance for Cardinal Health.
MDT - Medtronic Plc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Medtronic Plc (MDT). It includes detailed financial metrics such as market capitalization, income, sales, dividend information, various valuation ratios, and performance indicators. The report also highlights institutional and insider ownership, analyst recommendations, and recent stock performance.
KIDS,ATEC Volatility & Greeks
The article provides detailed financial and performance data for two medical device companies: OrthoPediatrics Corp (KIDS) and Alphatec Holdings Inc (ATEC). It includes current stock prices, market capitalization, earnings per share, sales figures, institutional and insider ownership, and various other financial ratios and performance metrics for both companies as of July 2nd.
If You Invested $1,000 in Exact Sciences Corp (EXAS)
This article analyzes the historical performance of a hypothetical $1,000 investment in Exact Sciences Corp (EXAS) over various periods, showing significant returns over 1 and 10 years but a loss over 5 years. It details Exact Sciences' business as a leading provider of cancer screening and diagnostic tests, including Cologuard and Oncotype DX, and mentions a proposed merger agreement with Abbott Laboratories. The article also provides a year-by-year return comparison of EXAS against the S&P 500.
CLPT - ClearPoint Neuro Inc Volatility & Greeks
This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The data presented covers the company's valuation, profitability, growth rates, and short interest.
Abbott Laboratories upgraded to Buy ahead of Q2 2026 earnings on growth from Exact Sciences acquisition
Abbott Laboratories has received an upgrade to Buy ahead of its Q2 2026 earnings report, following a significant drop in its share price. The upgrade is primarily driven by the anticipated high-growth cancer diagnostics segment from the recent Exact Sciences acquisition, projected to add $3 billion in incremental sales by 2026. Despite a slight EPS dilution from the acquisition, Abbott expects strong organic sales growth and adjusted EPS for 2026, supported by a robust balance sheet and improving core business.
SIBN - SI-BONE Inc Latest SEC Filings
This article provides detailed financial data and performance metrics for SI-BONE Inc (SIBN), including its latest stock price, market capitalization, earnings per share, sales, and various financial ratios. It also lists insider and institutional ownership, analyst recommendations, and recent price performance over different periods. The information is presented as a snapshot of the company's financial health and stock market activity.
If You Put $10,000 in This Dividend ETF 15 Years Ago, Here's How Much You'd Have Today (Hint: It's a Lot)
The Schwab U.S. Dividend Equity ETF (SCHD) has shown strong performance, returning approximately $61,200 from an initial $10,000 investment over 15 years, with dividends accounting for 38% of total returns. The ETF focuses on U.S. stocks with consistent dividends and strong financials. While SCHD is a solid investment, an S&P 500 index fund would have yielded even higher returns during the same period.
What Actually Drove IWD Over The Past Year
The article analyzes the performance of the iShares Russell 1000 Value ETF (IWD) over the past year, revealing that its significant return was primarily driven by a high concentration of gains from a few top-performing holdings like SanDisk and Micron Technology. Despite holding 865 positions, the five biggest contributors accounted for about 79% of the gains, highlighting that diversification by count does not always equate to diversified performance. The piece advises investors to be aware of where their real exposure lies and how concentrated gains within such funds affect their overall portfolio.
TNDM - Tandem Diabetes Care Inc Options
This article provides a detailed financial overview of Tandem Diabetes Care Inc. (TNDM), including its last closing price, market capitalization, key financial ratios, earnings per share, sales performance, and insider/institutional ownership. It also presents various performance metrics across different timeframes and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
If You Put $10,000 in This Dividend ETF 15 Years Ago, Here's How Much You'd Have Today (Hint: It's a Lot)
This article examines the performance of the Schwab U.S. Dividend Equity ETF (SCHD) over nearly 15 years. An initial investment of $10,000 in SCHD in October 2011 would be worth approximately $61,200 today, with dividends accounting for a significant portion of the total returns. While an S&P 500 index fund would have yielded even higher returns, SCHD remains a strong option for investors seeking both income and portfolio growth.
Is Index Shuffle And Probe Shift Reshaping The Investment Case For Abbott Laboratories (ABT)?
Abbott Laboratories (ABT) recently experienced an index shuffle, being added to the Russell 1000 Dynamic Index and removed from the Russell Top 50 Index. More significantly, the U.S. Department of Justice closed its criminal probe into Abbott's Michigan baby formula plant, opting for civil penalties instead, which clarifies legal exposure and removes a major regulatory overhang. This shift, combined with fresh analyst coverage and insider stock grants, suggests improved sentiment and reinforces the investment narrative around its diversified healthcare portfolio and product pipeline, despite ongoing pricing and regulatory risks.
Is Index Shuffle And Probe Shift Reshaping The Investment Case For Abbott Laboratories (ABT)?
Abbott Laboratories was recently added to the Russell 1000 Dynamic Index and had a criminal probe into its Michigan baby formula plant closed, with the U.S. Department of Justice now pursuing civil penalties instead. This shift clarifies legal exposure and removes a major overhang, improving sentiment and aligning leadership with shareholders. The company's investment narrative focuses on its diversified healthcare portfolio, product pipeline, and new device launches, with analysts projecting significant revenue and earnings growth and a fair value suggesting a 22% upside.
DOJ ends investigation into infant formula company linked to deadly cronobacter outbreak
The Department of Justice has closed its investigation into Abbott Laboratories, the infant formula manufacturer linked to a 2021-22 cronobacter outbreak that sickened four babies, killing two. This decision came after reports revealed Abbott contributed $500,000 to President Trump’s inauguration committee. Although prosecutors initially believed they had enough evidence for criminal charges, the DOJ opted to only reclaim funds from formula sales through federal nutrition programs.
Insulet Stock: A High-Quality Growth Story At A Reasonable PEG (NASDAQ:PODD)
Insulet (PODD) is rated a Buy due to its strong growth, low market penetration in diabetes management, and a recurring revenue model. The company's Omnipod system offers simplified diabetes care, driving sales and reducing patient burden. Despite concerns about GLP-1 drugs, Insulet targets insulin-dependent patients with significant room for growth, projecting a 60% upside to $260–270, supported by a 21% sales CAGR and a favorable PEG ratio compared to peers.
ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook
ResMed (RMD) saw its stock rise by 5.6% following its removal from several Russell growth indices, including the Russell 1000 Growth and Russell Midcap Growth benchmarks. This occurred as analysts became more optimistic about the company's earnings outlook, with upgraded rankings and higher profit estimates. The article suggests that while index removal primarily affects index flows, the improving analyst sentiment and upcoming Q4 fiscal 2026 earnings report on August 6 could significantly reshape ResMed's investment narrative.
Vermilion Energy (TSX:VET) Powers Global Gas Narrative
Vermilion Energy (TSX:VET) is enhancing its global natural gas presence through increased production, expanded Montney development, and growing international operations. The company's diversified portfolio across Canada, Europe, and Australia provides essential geographic and commodity diversification. An upcoming investor presentation will detail Vermilion's evolving international natural gas strategy, highlighting its continued progress in the sector.
PHG - Koninklijke Philips NV ADR Volatility & Greeks
This article provides a detailed financial overview of Koninklijke Philips NV ADR (PHG), including its current stock performance, key financial metrics, EPS trends, and insider/institutional ownership data. It presents a snapshot of the company's market position, dividend information, and analyst recommendations.
PHG - Koninklijke Philips NV ADR Earnings
This article provides a detailed financial overview of Koninklijke Philips NV (PHG) ADR, including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider/institutional ownership, and analyst recommendations.
What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders
Tandem Diabetes Care recently expanded its t:slim X2 insulin pump's compatibility with Abbott's FreeStyle Libre 3 Plus CGM in Europe, while facing new competition from Modular Medical's Pivot tubeless insulin patch pump. This dual development highlights both the growth of Tandem's ecosystem and increasing competitive pressures in the insulin delivery market. The article suggests this situation could lead to a mix of international expansion opportunities and risks from new tubeless rivals for Tandem shareholders.
Abbott (ABT) Clears A Major Legal Risk As DOJ Ends Criminal Formula Probe
The U.S. Department of Justice has closed its criminal investigation into Abbott Laboratories' Michigan baby formula plant, shifting focus to civil penalties for alleged manufacturing failures. This outcome clarifies a major regulatory risk for Abbott (ABT), whose stock recently closed at $90.74. Investors will now monitor how the company manages compliance and quality control to address operational and oversight expectations.
Trump Loaded Up on Abbott Laboratories Stock Before His DOJ Dropped Criminal Probe
Donald Trump purchased hundreds of thousands of dollars in Abbott Laboratories stock last year before his Justice Department ended a criminal investigation into the company, which was accused of misconduct related to infant deaths at one of its baby formula plants. Abbott had previously donated $500,000 to Trump's inaugural fund. The Justice Department reportedly shut down the investigation despite some prosecutors believing there was enough evidence for criminal charges, and Trump's DOJ has been noted for a lax approach to corporate enforcement.
Has Abbott Laboratories (ABT) Fallen Too Far Below Fair Value?
Abbott Laboratories stock has fallen 32.0% over the past year, but both its Discounted Cash Flow (DCF) intrinsic value estimate and traditional valuation multiples indicate it is trading at a discount. The company screens as undervalued in 6 of 6 valuation checks, suggesting it might be cheap despite ongoing legal and regulatory issues. The analysis points to a significant discount relative to cash flows and P/E ratio, raising the question of whether this gap offers a margin of safety or reflects justified compensation for risks.
Baird starts Abbott at Outperform, sees product pipeline driving growth By Investing.com
Baird has initiated coverage of Abbott Laboratories with an "Outperform" rating and a $121 price target, citing the company's diversified portfolio and upcoming product launches as drivers for stronger earnings growth. The brokerage anticipates 6% to 8% annual revenue growth and low-double-digit earnings growth, supported by leading positions in medical devices, diagnostics, nutrition, and established pharmaceuticals. Baird forecasts adjusted EPS of $5.46 in 2026 and $6.05 in 2027, expecting the valuation to improve as earnings resume growth after temporary dilution from the Exact Sciences acquisition.
Abbott Laboratories stock outperforms competitors on strong trading day
Abbott Laboratories (ABT) shares rallied 1.59% to $92.18 on Wednesday, outperforming the broader market during a dismal trading session. This gain broke a two-day losing streak for the stock, despite both the S&P 500 and Dow Jones Industrial Average experiencing declines.
Baird initiates Abbott stock coverage with Outperform rating
Baird has initiated coverage on Abbott Laboratories (NYSE:ABT) with an Outperform rating and a price target of $121, indicating a 33% upside. The firm anticipates steady 6-8% top-line and earnings growth for Abbott, driven by its strong medical devices business and strategic integrations. Abbott is considered undervalued, a prominent player in its industry, and has consistently raised its dividend for 12 years.
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care announced the launch of t:slim X2 insulin pump compatibility with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United Kingdom, Switzerland, Sweden, Finland, and Italy. This integration expands CGM choices for users of the t:slim X2 pump with Control-IQ+ automated insulin delivery technology. Additional countries, including Belgium, the Netherlands, and Germany, are expected to gain this compatibility in 2026.
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More
This article summarizes Wednesday's Wall Street analyst research calls, including upgrades, downgrades, and new initiations for various companies like Lockheed Martin, Salesforce, and Dow. It contextualizes these calls within the broader market performance, noting strong first-half returns for major U.S. indices despite concerns about overbought conditions and underperformance from the Magnificent 7. The report also provides updates on pre-market futures, treasury bonds, oil and gas, gold, and cryptocurrency markets.
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target. Additionally, Freedom Capital Markets started coverage on LivaNova PLC (LIVN) with a Hold rating, Raymond James initiated Amplitude Inc (AMPL) with a Strong Buy, B. Riley Securities began coverage on Lionsgate Studios Corp (LION) with a Neutral rating, and Wells Fargo initiated Honeywell Aerospace Inc (HONA) with an Equal-Weight rating. These analyst initiations highlight their current outlooks and price targets for these companies.
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care has launched the compatibility of its t:slim X2 insulin pump with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in five international markets: the UK, Switzerland, Sweden, Finland, and Italy. This integration provides more CGM choice for users of Tandem's Control-IQ+ automated insulin delivery technology, with plans to expand to additional countries like Belgium, the Netherlands, and Germany in 2026. The FreeStyle Libre 3 Plus sensor offers 15-day wear and sends minute-by-minute glucose readings to the pump and mobile app.
DXCM - Dexcom Inc Latest SEC Filings
This article provides the latest SEC filings information and comprehensive financial data for Dexcom Inc (DXCM). It details the company's recent stock performance, key financial metrics such as market cap, income, sales, P/E ratio, and growth rates. The information also includes insider and institutional ownership, profitability margins, and analyst recommendations.
TNDM - Tandem Diabetes Care Inc Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Tandem Diabetes Care Inc. (TNDM). It highlights key figures such as the last closing price, market capitalization, income, sales, various financial ratios, and stock performance over different periods. The data indicates recent stock movement, insider and institutional ownership, and profitability margins.
Integra LifeSciences Holdings (IART) Could Be 31% Undervalued Following Leadership Changes
Integra LifeSciences Holdings (IART) has restructured its commercial leadership, appointing new executives to enhance execution and customer focus. Despite a weak five-year shareholder return, the company shows strong recent momentum, trading at $18.74 with a fair value estimated at $27.00, suggesting it is 30.6% undervalued. This valuation is based on expected operational improvements, margin recovery, and long-term earnings growth, though regulatory and pricing risks remain.
1 Industrial Pioneer With a Plain-As-Day Moat to Buy and Never Sell
Linde (LIN) is presented as a strong buy-and-hold investment due to its robust business model, consistent dividend growth, and resilience during economic downturns. The company's "take-or-pay" contracts, significant backlog, and high operating margins ensure long-term stability. While it may lag in fast-paced bull markets, its attributes make it an ideal choice for retirement-focused investors seeking long-duration, low-maintenance allocation.
Abbott Laboratories stock underperforms Tuesday when compared to competitors
Abbott Laboratories (ABT) stock declined by 2.12% on Tuesday, closing at $90.74. This underperformance occurred despite a positive trading day for the broader market, with the S&P 500 and Dow Jones Industrial Average both seeing gains. This marks the second consecutive day of losses for the stock.
US criminal probe into Abbott infant-formula plant closed
The US Department of Justice has concluded its criminal investigation into Abbott Laboratories regarding bacterial contamination at its Michigan infant-formula plant. This closure follows a 2022 incident involving product recalls and facility closure due to Cronobacter sakazakii and Salmonella Newport infections in infants. Separately, Abbott plans to appeal a recent $53 million court ruling in favor of mothers who alleged a link between the company's formula and necrotizing enterocolitis (NEC) in babies.
US criminal probe into Abbott infant-formula plant closed
The US Department of Justice has concluded its criminal investigation into Abbott Laboratories regarding bacterial contamination at its infant-formula plant in Michigan. Abbott has agreed to a proposed settlement that will involve civil penalties under the US False Claims Act. This closure of the criminal probe follows a 2022 recall and plant shutdown due to Cronobacter sakazakii and Salmonella Newport concerns, which led to nationwide infant formula shortages.
Abbott Laboratories Federal Formula Safety Probe Quietly Shelved Following Massive Cash Injection To Donald Trump Fund
The US Justice Department has reportedly dropped a years-long criminal investigation into Abbott Laboratories regarding a contaminated baby formula plant, approximately 17 months after the company made a $500,000 donation to Donald Trump's inauguration. This decision to pursue civil clawbacks instead of criminal charges has drawn scrutiny from corporate accountability watchdogs. While there's no direct proof the donation influenced the outcome, the timing has raised suspicion, especially given the company's prior ties to the Trump administration.
EW - Edwards Lifesciences Corp Latest SEC Filings
This article provides the latest SEC filing information for Edwards Lifesciences Corp (EW), detailing various financial metrics, stock performance data, and insider/institutional ownership figures. It also includes key company statistics such as market cap, P/E ratio, sales, and employee count, alongside a summary of recent earnings and sales performance.
Abbott (ABT) EVP Cushman disposes 560 shares for tax withholding, retains 38,013
Elizabeth C. Cushman, Executive Vice President at Abbott Laboratories (ABT), reported a tax-related disposition of 560 common shares for tax withholding purposes. These shares were valued at $94.12 each. Following this transaction, Cushman directly retains 38,013 Abbott common shares, indicating the disposition was not an open-market sale but rather a routine tax obligation fulfillment.
Abbott Laboratories stock underperforms Monday when compared to competitors
Abbott Laboratories (ABT) stock declined by 1.50% on Monday, closing at $92.71, despite a positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, with SPX rising 1.18% and DJIA rising 0.59%. This fall ended a two-day winning streak for Abbott Laboratories.
Coca Cola Stock And 2 Defensive Picks For Steady Dividends
Amidst political tensions and market volatility, this article highlights three US blue-chip defensive stocks: Abbott Laboratories (ABT), Constellation Brands (STZ), and Coca-Cola (KO). These companies are presented as potentially resilient investments due to their essential products, strong cash generation, and steady dividends, despite facing challenges like debt, margin pressures, or tax disputes. The analysis suggests these stocks could provide stability when political factors influence market sentiment.
